https://elifesciences.org/articles/53934v2/figures
Figures and data in Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers | eLife
Single-molecule immunoprecipitation method reveals that the high catalytic rate and multi-tasking capability make a concerted contribution to the strong...
figures and data
https://www.uclahealth.org/news/release/asco-her3-targeted-antibody-drug-conjugate-adc-shows-promise
ASCO: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid...
A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard...
antibody drug conjugate
https://www.rcsb.org/structure/3P11
RCSB PDB - 3P11: anti-EGFR/HER3 Fab DL11 in complex with domains I-III of the HER3 extracellular...
anti-EGFR/HER3 Fab DL11 in complex with domains I-III of the HER3 extracellular region
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-her3-antibody-drug-conjugate-yl202
Definition of anti-HER3 antibody-drug conjugate YL202 - NCI Drug Dictionary - NCI
Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes...
antibody drug conjugatedefinition ofher3ncidictionary
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-egfr-her2-her3-monoclonal-antibody-mixture-sym013
Definition of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013 - NCI Drug Dictionary - NCI
Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes...
https://www.biospace.com/press-releases/her3-dxd-shows-promising-results-in-the-phase-ii-tuxedo-3-study-for-patients-with-limited-therapeutic-options
HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited...
https://www.biospace.com/press-releases/tharimmune-announces-positive-data-with-novel-biparatopic-pd-1-vegf-and-multispecific-her2-her3-biologics-leveraging-proprietary-epiclicktm-technology
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3...